SCHEMBL2335706

SCHEMBL2335706

Cn1c(=O)n(C(=O)NCC2CCN(CC(O)COc3ccc(Cl)cc3)CC2)c2ccccc21

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 3/20 0.55
CYP2D6 P10635 3/20 0.47
FAAH O00519 1/20 0.47
BCHE P06276 1/20 0.47
ACHE P22303 1/20 0.47
KMT2A Q03164 2/20 0.46
LMNA P02545 2/20 0.45
CACNA1G O43497 1/20 0.45
KCNH2 Q12809 1/20 0.45
MAPT P10636 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
HTR7 P34969 1/20 0.44
MEN1 O00255 1/20 0.44
MAPK1 P28482 1/20 0.44
RECQL P46063 1/20 0.44
HSD17B10 Q99714 1/20 0.44
CHRNA7 P36544 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2336627 0.93 DRD4 (0.53) DRD4CYP2D6CHRNA7
SCHEMBL2333287 0.92 DRD4 (0.55) DRD4CYP2D6FAAHACHEKMT2A
SCHEMBL2331954 0.92 TSHR (0.52) DRD4CYP2D6KMT2AMEN1CHRNA7
Hydrochloric Acid SCHEMBL3304278 0.91 TSHR (0.52) DRD4CYP2D6SMN1; SMN2
SCHEMBL2336040 0.90 USP2 (0.51) DRD4KMT2AMAPTSMN1; SMN2MEN1
SCHEMBL2334868 0.90 DRD4 (0.53) DRD4CYP2D6FAAHBCHEACHE
SCHEMBL2340631 0.90 HTR4 (0.57) DRD4CYP2D6FAAHBCHEACHE
SCHEMBL3299143 0.89 FAAH (0.46) DRD4CYP2D6FAAHBCHEACHE
SCHEMBL2333495 0.88 FAAH (0.43) DRD4CYP2D6FAAHBCHEACHE
SCHEMBL2334767 0.83 HTR4 (0.60) DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9593102-B2 Piperidine compounds, pharmaceutical composition comprising the same and its use SK BIOPHARMACEUTICALS CO., LTD. (KR) 2017-03-14 US claimed
US-20140135314-A1 PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE SK BIOPHARMACEUTICALS CO., LTD. (KR) 2014-05-15 US claimed
US-20190092727-A1 Piperidine Compounds, Pharmaceutical Composition Comprising The Same And Its Use SK BIOPHARMACEUTICALS CO., LTD. (KR) 2019-03-28 US disclosed
US-10144709-B2 Piperidine compounds, pharmaceutical composition comprising the same and its use SK BIOPHARMACEUTICALS CO., LTD. (KR) 2018-12-04 US disclosed
US-20170275250-A1 PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE SK BIOPHARMACEUTICALS CO LTD (KR) 2017-09-28 US disclosed
US-9676718-B2 Piperidine compounds, pharmaceutical composition comprising the same and its use SK BIOPHARMACEUTICALS CO., LTD. (KR) 2017-06-13 US disclosed
US-9593102-B2 Piperidine compounds, pharmaceutical composition comprising the same and its use SK BIOPHARMACEUTICALS CO., LTD. (KR) 2017-03-14 US disclosed
US-20160362374-A1 PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE SK BIOPHARMACEUTICALS CO LTD (KR) 2016-12-15 US disclosed
US-20140135314-A1 PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE SK BIOPHARMACEUTICALS CO., LTD. (KR) 2014-05-15 US disclosed
US-8642772-B2 Piperidine compounds, pharmaceutical composition comprising the same and its use SK BIOPHARMACEUTICALS CO., LTD. (KR) 2014-02-04 US disclosed
EP-2358702-B1 PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE SK BIOPHARMACEUTICALS CO LTD (KR) 2013-07-17 EP disclosed
EP-2358702-A2 PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE SK Holdings Co., Ltd. (KR) 2011-08-24 EP disclosed
WO-2010044585-A2 PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE SK HOLDINGS CO., LTD. (KR) 2010-04-22 WO disclosed
US-20100093801-A1 PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE SK HOLDINGS CO., LTD. (KR) 2010-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170275250-A1 PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE PGC, VIP, PIGO DRD4 317/4885CYP2D6 633/4885FAAH 849/4885
US-10144709-B2 Piperidine compounds, pharmaceutical composition comprising the same and its use PGC, VIP, PIGO DRD4 317/4885CYP2D6 633/4885FAAH 849/4885
US-20190092727-A1 Piperidine Compounds, Pharmaceutical Composition Comprising The Same And Its Use PGC, VIP, PIGO DRD4 317/4885CYP2D6 633/4885FAAH 849/4885
US-20160362374-A1 PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE PGC, VIP, PIGO DRD4 317/4885CYP2D6 633/4885FAAH 849/4885
US-20100093801-A1 PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE PGC, VIP, PIGO DRD4 317/4885CYP2D6 633/4885FAAH 849/4885
US-20140135314-A1 PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE PGC, VIP, PIGO DRD4 317/4885CYP2D6 633/4885FAAH 849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.